Ventricular function following drug-induced regression of hypertensive left ventricular hypertrophy

J R González-Juanatey1, C González-Juanatey

  • 1Division of Cardiology, Galician General Hospital, Santiago de Compostela, Spain.

Insights

Treating high blood pressure can reverse left ventricular hypertrophy (LVH) and improve heart function. This regression suggests underlying structural heart improvements, not just temporary blood pressure control.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Cardiovascular Physiology

Background:

  • Arterial hypertension frequently leads to left ventricular hypertrophy (LVH), a thickening of the heart's main pumping chamber.
  • LVH impairs diastolic function, affecting the heart's ability to fill properly.
  • Long-term effects of antihypertensive therapy on cardiac structure and function are crucial for patient outcomes.

Purpose of the Study:

  • To investigate the impact of drug-induced regression of LVH on diastolic efficiency in hypertensive patients.
  • To determine if improvements in systolic function persist long-term with antihypertensive treatment, specifically with ACE inhibitors.
  • To explore whether the regression of LVH involves reversible histological remodeling.

Main Methods:

  • Analysis of diastolic function and cavity filling in hypertensive patients undergoing LVH regression.
  • Long-term monitoring of systolic function in patients treated with ACE inhibitors.
  • Assessment of ventricular function following abrupt withdrawal of antihypertensive medication.

Main Results:

  • Drug-induced LVH regression is associated with enhanced diastolic filling due to improved structural and functional determinants.
  • Long-term ACE inhibitor therapy in hypertensive patients with LVH regression leads to sustained improvements in systolic function.
  • Discontinuation of antihypertensive medication, despite a return to pre-treatment blood pressure, did not cause similar deterioration in ventricular function.

Conclusions:

  • Regression of LVH through antihypertensive medication improves both diastolic and long-term systolic function.
  • The sustained ventricular function after drug withdrawal suggests a reversal of histological cardiac remodeling.
  • These findings highlight the benefits of addressing underlying structural changes in hypertensive heart disease.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...